AMR clinical trials at UCLA

1 in progress, 0 open to eligible people

ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Sorry, in progress, not accepting new patients
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
Los Angeles 5368361, California 5332921 and other locations

Last updated: June 19, 2025